Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis.
We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentivi...
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
BMJ Publishing Group
2016
|
| _version_ | 1826257729370456064 |
|---|---|
| author | Alton, E Beekman, J Boyd, A Brand, J Carlon, M Connolly, M Chan, M Conlon, S Davidson, H Davies, J Davies, L Dekkers, J Doherty, A Gea-Sorli, S Gill, D Griesenbach, U Hasegawa, M Higgins, T Hironaka, T Hyndman, L McLachlan, G Inoue, M Hyde, S Innes, J Maher, T Moran, C Meng, C Paul-Smith, M Pringle, I Pytel, K Rodriguez-Martinez, A Schmidt, A Stevenson, B Sumner-Jones, S Toshner, R Tsugumine, S Wasowicz, M Zhu, J |
| author_facet | Alton, E Beekman, J Boyd, A Brand, J Carlon, M Connolly, M Chan, M Conlon, S Davidson, H Davies, J Davies, L Dekkers, J Doherty, A Gea-Sorli, S Gill, D Griesenbach, U Hasegawa, M Higgins, T Hironaka, T Hyndman, L McLachlan, G Inoue, M Hyde, S Innes, J Maher, T Moran, C Meng, C Paul-Smith, M Pringle, I Pytel, K Rodriguez-Martinez, A Schmidt, A Stevenson, B Sumner-Jones, S Toshner, R Tsugumine, S Wasowicz, M Zhu, J |
| author_sort | Alton, E |
| collection | OXFORD |
| description | We have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentiviral vectors are more efficient for lung gene transfer than non-viral vectors in preclinical models. In preparation for a first-in-man CF trial using the lentiviral vector, we have undertaken key translational preclinical studies. Regulatory-compliant vectors carrying a range of promoter/enhancer elements were assessed in mice and human air-liquid interface (ALI) cultures to select the lead candidate; cystic fibrosis transmembrane conductance receptor (CFTR) expression and function were assessed in CF models using this lead candidate vector. Toxicity was assessed and 'benchmarked' against the leading non-viral formulation recently used in a Phase IIb clinical trial. Integration site profiles were mapped and transduction efficiency determined to inform clinical trial dose-ranging. The impact of pre-existing and acquired immunity against the vector and vector stability in several clinically relevant delivery devices was assessed. A hybrid promoter hybrid cytosine guanine dinucleotide (CpG)- free CMV enhancer/elongation factor 1 alpha promoter (hCEF) consisting of the elongation factor 1α promoter and the cytomegalovirus enhancer was most efficacious in both murine lungs and human ALI cultures (both at least 2-log orders above background). The efficacy (at least 14% of airway cells transduced), toxicity and integration site profile supports further progression towards clinical trial and pre-existing and acquired immune responses do not interfere with vector efficacy. The lead rSIV.F/HN candidate expresses functional CFTR and the vector retains 90-100% transduction efficiency in clinically relevant delivery devices. The data support the progression of the F/HN-pseudotyped lentiviral vector into a first-in-man CF trial in 2017. |
| first_indexed | 2024-03-06T18:22:47Z |
| format | Journal article |
| id | oxford-uuid:06e16f3b-e8eb-4ccb-b37f-5e85a5a75530 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:22:47Z |
| publishDate | 2016 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:06e16f3b-e8eb-4ccb-b37f-5e85a5a755302022-03-26T09:04:50ZPreparation for a first-in-man lentivirus trial in patients with cystic fibrosis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:06e16f3b-e8eb-4ccb-b37f-5e85a5a75530EnglishSymplectic Elements at OxfordBMJ Publishing Group2016Alton, EBeekman, JBoyd, ABrand, JCarlon, MConnolly, MChan, MConlon, SDavidson, HDavies, JDavies, LDekkers, JDoherty, AGea-Sorli, SGill, DGriesenbach, UHasegawa, MHiggins, THironaka, THyndman, LMcLachlan, GInoue, MHyde, SInnes, JMaher, TMoran, CMeng, CPaul-Smith, MPringle, IPytel, KRodriguez-Martinez, ASchmidt, AStevenson, BSumner-Jones, SToshner, RTsugumine, SWasowicz, MZhu, JWe have recently shown that non-viral gene therapy can stabilise the decline of lung function in patients with cystic fibrosis (CF). However, the effect was modest, and more potent gene transfer agents are still required. Fuson protein (F)/Hemagglutinin/Neuraminidase protein (HN)-pseudotyped lentiviral vectors are more efficient for lung gene transfer than non-viral vectors in preclinical models. In preparation for a first-in-man CF trial using the lentiviral vector, we have undertaken key translational preclinical studies. Regulatory-compliant vectors carrying a range of promoter/enhancer elements were assessed in mice and human air-liquid interface (ALI) cultures to select the lead candidate; cystic fibrosis transmembrane conductance receptor (CFTR) expression and function were assessed in CF models using this lead candidate vector. Toxicity was assessed and 'benchmarked' against the leading non-viral formulation recently used in a Phase IIb clinical trial. Integration site profiles were mapped and transduction efficiency determined to inform clinical trial dose-ranging. The impact of pre-existing and acquired immunity against the vector and vector stability in several clinically relevant delivery devices was assessed. A hybrid promoter hybrid cytosine guanine dinucleotide (CpG)- free CMV enhancer/elongation factor 1 alpha promoter (hCEF) consisting of the elongation factor 1α promoter and the cytomegalovirus enhancer was most efficacious in both murine lungs and human ALI cultures (both at least 2-log orders above background). The efficacy (at least 14% of airway cells transduced), toxicity and integration site profile supports further progression towards clinical trial and pre-existing and acquired immune responses do not interfere with vector efficacy. The lead rSIV.F/HN candidate expresses functional CFTR and the vector retains 90-100% transduction efficiency in clinically relevant delivery devices. The data support the progression of the F/HN-pseudotyped lentiviral vector into a first-in-man CF trial in 2017. |
| spellingShingle | Alton, E Beekman, J Boyd, A Brand, J Carlon, M Connolly, M Chan, M Conlon, S Davidson, H Davies, J Davies, L Dekkers, J Doherty, A Gea-Sorli, S Gill, D Griesenbach, U Hasegawa, M Higgins, T Hironaka, T Hyndman, L McLachlan, G Inoue, M Hyde, S Innes, J Maher, T Moran, C Meng, C Paul-Smith, M Pringle, I Pytel, K Rodriguez-Martinez, A Schmidt, A Stevenson, B Sumner-Jones, S Toshner, R Tsugumine, S Wasowicz, M Zhu, J Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. |
| title | Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. |
| title_full | Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. |
| title_fullStr | Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. |
| title_full_unstemmed | Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. |
| title_short | Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. |
| title_sort | preparation for a first in man lentivirus trial in patients with cystic fibrosis |
| work_keys_str_mv | AT altone preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT beekmanj preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT boyda preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT brandj preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT carlonm preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT connollym preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT chanm preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT conlons preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT davidsonh preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT daviesj preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT daviesl preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT dekkersj preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT dohertya preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT geasorlis preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT gilld preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT griesenbachu preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT hasegawam preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT higginst preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT hironakat preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT hyndmanl preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT mclachlang preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT inouem preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT hydes preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT innesj preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT mahert preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT moranc preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT mengc preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT paulsmithm preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT pringlei preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT pytelk preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT rodriguezmartineza preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT schmidta preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT stevensonb preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT sumnerjoness preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT toshnerr preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT tsugumines preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT wasowiczm preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis AT zhuj preparationforafirstinmanlentivirustrialinpatientswithcysticfibrosis |